Activity of and resistance to moxifloxacin in Staphylococcus aureus. - Wikidata - wikimedia - TriplyDB

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

http://www.wikidata.org/entity/Q34885313

about

Antimicrobial resistance: the example of Staphylococcus aureus Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.Profile of microbial keratitis after corneal collagen cross-linking.In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.Moxifloxacin in the treatment of skin and skin structure infections.Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Quinolone resistance due to reduced target enzyme expression Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr.Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.Tissue concentrations of vancomycin and Moxifloxacin in periprosthetic infection in rats.Resistance of canine methicillin-resistant Staphylococcus pseudintermedius strains to pradofloxacin.Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus

P2860

Q24676363-7EE9F8C3-F245-4013-BA68-81CFE4809D43 Q33555316-23D731E3-557B-4E80-B8FB-4D642C2EB636 Q33770013-2019F373-978B-4B04-AAF0-F7FD12EF10C0 Q33812856-62EECD30-E355-499C-9812-B0A7E6C4AE5C Q33836603-D5B3F570-D1FE-4582-AD1B-18FD73EF6F77 Q34228402-C1ABB883-7235-4535-92AA-CCABE87C0FA5 Q34271007-1ACC1364-5BF5-4630-8854-8B4BCE4D13CC Q35005092-8DED7F19-1201-495B-AF00-6D70BD0F8A70 Q35919259-BFFFA24D-26D5-4E25-9501-655858C16547 Q36669771-1DD86A57-82F1-4C0D-AD1E-7B4A5EB08E89 Q36718474-6BCFF762-B7E5-4DFA-82BA-B5EB441E5464 Q37062733-3EBE42DD-3AA5-426C-B6E2-3A1EB8A360D0 Q37121180-58D130AE-584A-43A8-BAEC-33CBA95A6FA0 Q37286906-595E6C3F-CF6B-4AC3-A217-7894862F72AE Q37577369-A935F194-80B1-49CE-B56F-CC5C42DA42B7 Q37612996-2BB51A41-485C-457D-A94E-94E4CD69835E Q40128872-EC1C93CA-1DC4-4B6C-8ED9-935887E482DD Q40602923-7909A72B-54F8-44AB-B2BD-2C5429362215 Q40953254-2DE2C8C4-9BCE-444B-80A1-CFD3E050DF17 Q41822811-31132F07-F331-461A-AF31-D2C262928750 Q41925162-B1BE2AA4-3C2B-41A2-BC67-410E96DB7988 Q42116070-F08AAED5-93CC-4203-A469-A5287A37C23C Q42231593-99DBE017-D9D5-405A-91EB-051B1BE1E27C Q42624603-1D999D72-EA87-4DC3-92D1-1EEE337A4F47

P2860

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

http://www.wikidata.org/entity/Q34885313

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@ast

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@en

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@nl

type

label

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@ast

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@en

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@nl

prefLabel

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@ast

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@en

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@nl

P1433

Q34885313-FE64B204-642C-492A-B3B2-DE63C27BC793

P1476

Q34885313-93630B2B-F697-47D8-B19A-7E425F93EB90

P2093

Q34885313-347423CA-7E55-4D4F-9CDB-B065CE11E69E

Q34885313-C3A03B9A-DE4B-432F-8CB0-9849716C1A17

Q34885313-D05831F5-4BF5-4A5A-BCDC-67653A5CFC9B

P2860

Q34885313-010C510B-E321-4448-A822-68DD53A32698

Q34885313-0ACCD3A8-CA78-44ED-9939-C9EF7C2B1F6B

Q34885313-1B6DEE1A-372E-43C3-B06E-6E7CF03A77AA

Q34885313-1C8F7E7C-EFD9-4D74-93B1-E9C1872FFD32

Q34885313-298A546B-DC72-4A40-896E-AA804F566958

Q34885313-2D1C70AA-0E8F-4331-91D1-8088D9A901EE

Q34885313-30070DE2-788D-4D26-8DC9-72C3999FB662

Q34885313-30161005-473C-46E3-A7E4-33836784AE60

Q34885313-39BDD5ED-C3DE-44BD-973D-DF3FD42E29F5

Q34885313-3D84FA87-263A-428F-A266-588CEAD43E6C

P304

Q34885313-AB9F837B-9656-4EC3-A09C-347A7707CF68

P31

Q34885313-4C4C10F7-195C-47D0-B6F8-314109A419F1

P356

Q34885313-24ECF380-10F5-4451-9FB9-15890F956CF3

P407

Q34885313-1DB451BE-9F02-46EB-876D-185EA3019201

P433

Q34885313-121BEF60-9F15-4EA7-97BC-CDFDD467C50E

P478

Q34885313-AD12040C-74A4-43C7-A689-C68C5639E1A6

P577

Q34885313-BDB89F32-0E8C-4C6E-A6E0-C00CE186E3CE

P5875

Q34885313-39696EBA-AF88-4233-A42A-28BC4235D8FE

P698

Q34885313-C843731B-02E8-4A7B-882C-A6EBF1B13707

P932

Q34885313-1C8EE61F-FD20-494C-8C9A-339E9BFFA9F6

P356

AAC.47.4.1410-1415.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

@en

P2093

David C Hooper

http://www.w3.org/2001/XMLSchema#string

Dilek Ince

http://www.w3.org/2001/XMLSchema#string

Xiamei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus

Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria

Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance

Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance

In vitro activity of BAY 12-8039, a new fluoroquinolone

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.

Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.

ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.

P304

1410-1415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.4.1410-1415.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10839882

http://www.w3.org/2001/XMLSchema#string

P698

12654680

http://www.w3.org/2001/XMLSchema#string

P932

152517

http://www.w3.org/2001/XMLSchema#string